CEL-SCI Corp.’s (NYSE MKT: CVM)
body of work with the human immune system is one of perseverance and a passion
for survival despite odds that would make the vast majority of biotech
companies fold their tents and choose easier endeavors. Faced with trending
downturns in the biotech sector, limited funding, and an arduous clinical trial
process connected with the development of its investigational therapy for
advanced primary head and neck cancer, the company’s mission is now well within
sight. CVM’s lead investigational immunotherapy, Multikine® (Leukocyte
Interleukin, Injection), has been tested in Phase I and II clinical trials, and
is now enrolling patients for a global Phase III trial.
The inception of CVM’s journey
began at the Max Planck Institute in Germany in the late 1970s and has been
fueled with science and research supporting the theory that the immune system
is inherently a cancer fighter. Company founder, Maximilian de Clara, believed
strongly that the immune system is pivotal in fighting this disease, but he did
not have the technology to transition his concept to product. Brushing off
discouragement, Maximilian funded the early Multikine research at the Max Plank
Institute in 1978, founded CEL-SCI around the idea of Multikine in 1983, and
later took CVM public.
The company’s mission is to
improve the treatment of cancer and other diseases by utilizing the immune
system. CEL-SCI Corp. aims to create shareholder value by developing unique
therapies that address medical needs that are commonly unmet. The company is
dedicated to developing its therapies using a scientific and data-driven
approach.
CVM’s undying spirit aims to be
science-based and data driven – taking no shortcuts on its road to drug
development. The company is steadfast in its ethics and integrity while being
economical in its daily approach to creating shareholder value.
Multikine is the registered
trademark under which CEL-SCI has its investigational therapy. The proprietary
name is subject to FDA review in connection with additional, anticipated
regulatory submission for approval measures. Multikine has not been licensed or
approved for sale by the FDA or any other regulatory agency at this time and
its safety or efficacy has not been established for any use. Further research
is required, and early-phase clinical trial results must be confirmed in Phase
III clinical trials, which are currently underway. CEL-SCI Corporation is
headquartered in Vienna, Virginia.
For more information on this
company visit http://www.cel-sci.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment